PMID- 21864043
OWN - NLM
STAT- MEDLINE
DCOM- 20111220
LR  - 20220317
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 52
IP  - 9
DP  - 2011 Sep
TI  - Allogeneic hematopoietic cell transplant for multiple myeloma using reduced 
      intensity conditioning therapy, 1998-2006: factors associated with improved 
      survival outcome.
PG  - 1727-35
LID - 10.3109/10428194.2011.582201 [doi]
AB  - This study reports on the outcome of 95 allogeneic hematopoietic cell transplants 
      (HCTs) using reduced intensity conditioning (RIC) performed for patients with 
      multiple myeloma (MM) in Australia and New Zealand between 1998 and 2006. The 
      median age at HCT was 52 years. Of the 32 patients for whom the allograft was 
      performed as a first transplant, 15 (47%) had their allograft less than 1 year 
      from diagnosis, while for the 63 patients who had an allograft following an 
      autograft, nine (14%) were allografted within 1 year post-diagnosis (p < 0.001). 
      The cumulative incidence of transplant-related mortality (TRM) was 19% at 1 year 
      post-transplant. At 5 years post-transplant the overall survival (OS) was 40% and 
      progression-free survival (PFS) was 23%, with no apparent survival plateau. Three 
      factors were independently favorable predictors of OS in a Cox regression model: 
      immunoglobulin G (IgG) myeloma (hazard ratio [HR] = 0.42, 95% confidence interval 
      [CI] 0.24-0.75, p = 0.004), a human leukocyte antigen (HLA)-identical sibling 
      donor (HR = 0.37, 95% CI 0.18-0.74, p = 0.005), and less than 1 year between MM 
      diagnosis and RIC HCT (HR = 0.27, 95% CI 0.12-0.59, p = 0.001). Patterns of 
      outcome indicate that RIC HCT may offer the potential for cure for only a small 
      group of patients with MM.
FAU - Nivison-Smith, Ian
AU  - Nivison-Smith I
AD  - Australasian Bone Marrow Transplant Recipient Registry, Darlinghurst, NSW, 
      Australia. inivisonsmith@stvincents.com.au
FAU - Dodds, Anthony J
AU  - Dodds AJ
FAU - Doocey, Richard
AU  - Doocey R
FAU - Ganly, Peter
AU  - Ganly P
FAU - Gibson, John
AU  - Gibson J
FAU - Ma, David D F
AU  - Ma DD
FAU - Simpson, Judy M
AU  - Simpson JM
FAU - Szer, Jeff
AU  - Szer J
FAU - Bradstock, Kenneth F
AU  - Bradstock KF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
SB  - IM
MH  - Adult
MH  - Australia
MH  - Female
MH  - Graft vs Host Disease/etiology/prevention & control
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/*mortality/*therapy
MH  - New Zealand
MH  - Tissue Donors
MH  - *Transplantation Conditioning
MH  - Transplantation, Homologous
MH  - Treatment Outcome
EDAT- 2011/08/26 06:00
MHDA- 2011/12/21 06:00
CRDT- 2011/08/26 06:00
PHST- 2011/08/26 06:00 [entrez]
PHST- 2011/08/26 06:00 [pubmed]
PHST- 2011/12/21 06:00 [medline]
AID - 10.3109/10428194.2011.582201 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2011 Sep;52(9):1727-35. doi: 10.3109/10428194.2011.582201.